Fusion Antibodies PLC
LSE:FAB
Fusion Antibodies PLC
LSE:FAB
Price:
3.75 GBX
Market Closed
Updated:
Apr 27, 2024
Fusion Antibodies PLC
Cash from Operating Activities
|
Fusion Antibodies PLC
Cash from Operating Activities Peer Comparison
Comparables:
ONT
O
ORPH
DXRX
ERGO
HVO
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Fusion Antibodies PLC
LSE:FAB
|
Cash from Operating Activities
-£2.4m
|
CAGR 3-Years
-91%
|
CAGR 5-Years
-41%
|
CAGR 10-Years
N/A
|
|
|
Oxford Nanopore Technologies PLC
LSE:ONT
|
Cash from Operating Activities
-£137.3m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
N/A
|
|
O
|
Open Orphan PLC
LSE:ORPH
|
Cash from Operating Activities
£16m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Diaceutics PLC
LSE:DXRX
|
Cash from Operating Activities
£5.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
|
|
Ergomed PLC
LSE:ERGO
|
Cash from Operating Activities
£19.3m
|
CAGR 3-Years
5%
|
CAGR 5-Years
50%
|
CAGR 10-Years
N/A
|
|
|
hVIVO PLC
LSE:HVO
|
Cash from Operating Activities
£17.2m
|
CAGR 3-Years
60%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Fusion Antibodies PLC's Cash from Operating Activities?
Cash from Operating Activities
-2.4m
GBP
-2.4m
GBP
Based on the financial report for Sep 30, 2023, Fusion Antibodies PLC's Cash from Operating Activities amounts to -2.4m GBP.
What is Fusion Antibodies PLC's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-41%
-41%
Over the last year, the Cash from Operating Activities growth was -310%. The average annual Cash from Operating Activities growth rates for Fusion Antibodies PLC have been -91% over the past three years , -41% over the past five years .
You don't have any saved screeners yet
